Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

Housing & Urban Development Corp., Paras Defence and Space Technologies Ltd. and Waaree Energies Ltd. are some stocks that ...

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Stocks like Jio Financial Services, Can Fin Homes, Seshasayee Paper, Supreme Petrochem, 5paisa Capital, ICICI Lombard General ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...

Rural India is emerging as a key market for FMCG companies due to rising disposable incomes, driven by robust agricultural output and government schemes. Companies are increasing their presence with ...

FMCG companies are expanding into rural areas where consumption is growing faster than in urban areas, driven by higher ...

Nomura has upgraded Zydus Lifesciences Ltd. to a 'buy' from its earlier 'neutral' stance, raising the target price to Rs 1,140 from Rs 1,030, implying a potential upside of 16%. Robust earnings growth ...